![](https://www.clevelandhiv.org/wp-content/uploads/2021/10/blue-yellow-antibodies-570x300.jpeg)
SAB-185 Polyclonal Antibody Graduates to Phase 3 The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the […]